Swiss Biotech’s Immunotherapy for Brain Cancer gets Orphan Drug Designation – Labiotech.eu (blog)
Labiotech.eu (blog) |
Swiss Biotech's Immunotherapy for Brain Cancer gets Orphan Drug Designation
Labiotech.eu (blog) The FDA will give special treatment to Vaximm's oral T cell immunotherapy for glioma, which is particularly difficult to treat. Vaximm focuses on the development of oral T cell immunotherapies for cancers. The FDA and European Commission have given … |
